Novo Nordisk is a global healthcare company with almost 100 years of innovation and leadership in diabetes care. This heritage gives us the experience and capabilities that enable us to help people defeat other serious chronic diseases: hemophilia, growth disorders and obesity. The company’s two Phase Three trials (evoke and evoke+) in early Alzheimer’s Disease are now fully enrolled and ongoing.